Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-hepatic oxaliplatin plus systemic capecitabine with or without trastuzumab for non-resectable breast cancer liver metastases
2009-014863-37Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, capecitabine and trastuzumab in breast cancer (2 arms), sponsored by Herlev Hospital. Primary endpoint: Response rate. Started Aug 2009; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-014863-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014863-37.